CN101167899A - Medicine for treating diabetes and its preparation method - Google Patents
Medicine for treating diabetes and its preparation method Download PDFInfo
- Publication number
- CN101167899A CN101167899A CNA2007101140112A CN200710114011A CN101167899A CN 101167899 A CN101167899 A CN 101167899A CN A2007101140112 A CNA2007101140112 A CN A2007101140112A CN 200710114011 A CN200710114011 A CN 200710114011A CN 101167899 A CN101167899 A CN 101167899A
- Authority
- CN
- China
- Prior art keywords
- medicine
- carapax
- clear water
- weight
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicament for curing diabetes mellitus and process for preparation. According to the weight proportioning, the invention is made by the raw materials of turtle shell 35-45 parts after the acid and alkaline hydrolysis, chinemys reevesii 35-45 parts after the acid and alkaline hydrolysis, cornucervi pantotrichum 5-15 parts, and saffron 5-15 parts. The process for preparation is that the medicament of the invention is made by an even mixture of turtle shell powders, chinemys reevesii powders, cornucervi pantotrichum powders, and saffron powders. The medicament prepared by the invention can be capsules, powder medicaments and tablets. The invention is capable of decreasing the blood sugar to the normal range after taking the medicament by diabetes mellitus patients at the first stage, and the invention is capable of decreasing the doses of the western medicines by the patients at the middle stage greatly. The example number of the patients of which the illness histories are more than 15 years accompanied with complications is 70, after taking the invention of 15 months, the taking amount of the western medicine is capable of decreasing 80%. The patient can take 20% of the prior medicines every night, further the patient can take the medicine once every other day, thereby the blood sugar and the glucose in urine keep normal, and the self feeling is good without any rebound after the tracking observation of 2 years.
Description
Technical field
The present invention relates to medicine, particularly a kind of medicine for the treatment of diabetes and preparation method thereof.
Background technology
Diabetes are one of higher diseases of sickness rate in the world, and sickness rate was and increases situation year by year in recent years.All diabeticss must rely on takes Western medicine existence.Though the side effect of Western medicine is bigger, taking for a long time has bigger infringement to biological activity in kidney, liver and the body etc.,, remove this type of medicine and can not keep blood glucose in normal range.
The domestic Chinese medicine that discloses more multiple treatment diabetes, still, the effect after taking is not good enough, and the medicine of part better effects still needs to cooperate the western drug amount of taking 60-80%.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of diabetes and preparation method thereof, after it can make diabetics take at the initial stage of a disease, blood glucose was reduced in normal range, make the mid-term patient significantly reduce dose to Western medicine etc.
The present invention for achieving the above object, be achieved through the following technical solutions: a kind of medicine for the treatment of diabetes, it is made by the following weight proportion raw material: the Carapax Trionycis 35-45 part after decomposing through soda acid, through the Carapax et Plastrum Testudinis 35-45 part after the soda acid decomposition, Cornu Cervi Pantotrichum 5-15 part, Stigma Croci 5-15 part.
Described a kind of medicine for the treatment of diabetes, it is made by the following weight proportion raw material, and 40 parts of the Carapax Trionycis after decomposing through soda acid are through 40 parts of the Carapax et Plastrum Testudiniss after the soda acid decomposition, 10 parts in Cornu Cervi Pantotrichum, 10 parts of Stigma Crocis.
Described a kind of preparation method for the treatment of the medicine of diabetes, putting into container after Carapax Trionycis, Carapax et Plastrum Testudinis cleaned soaked 10-13 hour with acidic liquid, the weight of vinegar is the 6%-8% of clear water weight in the liquid, and property among taking-up is dashed with clear water after soaking is dried standby;
Above-mentioned standby Carapax Trionycis, Carapax et Plastrum Testudinis are put into akaline liquid again soaked 10-13 hour, the weight of alkali is the 10%-12% of clear water weight in the akaline liquid, and property was dried standby among the taking-up clear water dashed after soaking;
To put into acidic liquid for the second time through Carapax Trionycis, Carapax et Plastrum Testudinis that akaline liquid soaks and soak 10-13 hour, the weight of vinegar is the 4%-6% of clear water weight in the liquid, and property among the taking-up clear water dashes after soaking is dried standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after the second time, acidic liquid soaked are put into akaline liquid again soaked 10-13 hour, the weight of the alkali in the liquid is the 8%-10% of clear water weight, and property among the taking-up clear water dashes after soaking is dried standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after will handling through above-mentioned operation be put into inherent 78 ℃ of-82 ℃ of scopes insulation of constant temperature oven 46-50 hour, take out that to be crushed to powdery after drying standby;
Cornu Cervi Pantotrichum inserted in the steam steamed 2-3 hour, add the rice wine that accounts for clear water weight 8%-10% at the clear water that is used for producing steam, the Cornu Cervi Pantotrichum after steaming is dried the back oven drying at low temperature, and to be crushed to powdery standby;
Stigma Croci is cleaned the back oven drying at low temperature, and to be crushed to powdery standby;
To make medicine of the present invention behind above-mentioned turtle ' s carapace powder, Tortoise Shell, Pulveratum Cornu Cervi Pantotrichum and the safranine pollen mix homogeneously.
The made medicine of the present invention is capsule, powder or tablet.
Carapax Trionycis in the medicine of the present invention, Carapax et Plastrum Testudinis through soda acid decompose will be wherein calcareous, impurity and protein repeatedly decompose removal, reducing calcium, impurity and Protein content in the medicine, thereby reduce the scorching influence of the deficiency of YIN in patient's body.Medicament composing prescription nourishing YIN and clearing away heat of the present invention, mediator's yin-yang, reinforcing the kidney and supporting YANG, blood circulation promoting and blood stasis dispelling, removing heat from the liver fills blood, the meridian dredging.Show through animal experiment:
(1) body weight to diabetes rat has tangible promotion accretion, and high dose group and low dose group rat and model control group rat compare utmost point significance and significant differences respectively.
(2) blood sugar increasing to diabetes rat has tangible reduction effect, and high dose group and low dose group too Mus and model control group rat compare utmost point significant difference is all arranged.Analyze its reason, discovery can increase not tip tissue to the picked-up and the processing effect of sugar, and inhibition glycogen heteroplasia, thereby blood sugar lowering simultaneously, it can increase the deoxyglucose basis, inside and outside or insulin stimulating or glucose absorption, and the while has also increased the quantity with the membrane plasmapheresis bound insulin, and can strengthen sugar carrier GluT1 and the proteic expression of GluT4, accelerate the blood glucose metabolic rate, thus blood sugar lowering.
(3) to the influence of lipid metabolism.Can reduce triglyceride in the serum (TG) and free fatty, high density lipoprotein total to serum (HDL) and low density lipoprotein, LDL can be not influential.
(4) blood pressure to diabetes rat increases, and especially systolic pressure increases tangible reduction effect, and high dose group and low dose group rat and model control group rat compare utmost point significance and significant differences respectively.
(5) plasma viscosity to rat has tangible reduction effect, and high dose group and low dose group rat and model control group rat compare highly significant performance difference and significant difference respectively.
Toxicity test shows that medicine of the present invention is without any side effects, can take for a long time, and laboratory report is as follows:
Method: irritate the stomach dose so that mice 24h is maximum, and disposable maximum lumbar injection dose represents maximum tolerated dose, rat press 20 times of clinical medicine doses, 10 times, 5 times grouping filling stomaches 30 days, makes long term toxicity test.The result: maximum tolerated dose is 4980mg/kg.w, be 124.5 times of clinical consumption, disposable maximum lumbar injection dose 16660mg/kg b.w, two groups of mices all survive, three groups of rat medicine feeds three months, all survivals, every biochemical indicators such as body weight and routine blood test, liver, renal function, blood glucose, blood fat are all normal, rat is dissected, the pathologic finding and the normal control indifference opposite sex.
Conclusion: oral for a long time, have no side effect, safe in utilization.
The purification raw material: effective ingredient reaches more than 92%, heavy metal inspection＜10mg/kg, insoluble ashes＜0.02%.
One, method and result: the maximum tolerated dose experiment of irritating stomach:
Method: 20 mices, water is can't help in 12h fasting before the experiment, concentration is that the medicinal liquid of 83mg/ml divides three times to every mouse stomach, and 24h irritates the total dose of stomach and reaches 1.2ml, (being equivalent to 498mg/kgb.w), be equivalent to 124.5 times of adult's clinical administration daily dose, irritate stomach time and dosage:
| For the first time | 8:00Am | Irritate stomach 0.5ml for every |
| For the second time | 12:00Am | Irritate stomach 0.4ml for every |
| For the third time | 4:00Am | Irritate stomach 0.3ml for every |
The result: 1,20 none death of mice, continue to observe 10d all slow (seeing Table 1)
2,20 mices abdominal tympanites occurs after irritating stomach, breathe and quicken, and are slow in action, and appetite reduces, and the feces color and luster is rare soft;
3, behind the 3d, above-mentioned symptom disappears, the feces molding, and it is normal that diet recovers;
4, raise continuation after the mice administration routinely and observe 10d, outward appearance, diet, activity recover normal.
Survival condition behind table 1 mouse stomach
| The experiment natural law | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Survival Mus number (n) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Dead Mus number (n) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The acute toxicity testing of lumbar injection:
Method: 12h fasting before 20 mouse experiments, can't help water, be the medicinal liquid lumbar injection of 83mg/ml with compound concentration, every injected in mice amount is 0.4kml (being equivalent to 1660mg/kgb.w)
Result: 1,20 mices all survive (seeing Table 2);
2, raise continuation routinely and observe 10d, outward appearance, diet, movable normal.
Survival condition behind the table 2 mouse peritoneal injection drug
| The experiment natural law | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Survival Mus number (n) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Dead Mus number (n) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Two, drug with little toxicity experiment:
Method: get 80 of SD rats, male and female half and half are divided into four groups at random, 20 every group;
Heavy dose of group: press 1.8g/kg/d and irritate stomach, quite clinical 20 times;
Successive administration 90d, observe and respectively organize the rat ordinary circumstance, (active state, diet, feces, body weight change etc.), the system that checks before the administration after routine blood test, liver, renal function, blood glucose, blood fat etc. and the administration becomes celestial and (comprising 12 kinds of organs and tissues such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus, stomach, small intestinal, large intestine, testis, ovary) looked in the diseased tissues blood examination;
Result: see Table 3 respectively, table 4, table 5, table 6;
Medication group and control rats be all survivals in 90 day experimental period;
Body weight change:
4 treated animal body weight gain situation basically identicals see Table 3.
The influence of table 3 pair rat body weight
| Group | Number of animals | Body weight (g) | |||
| n | Before irritating stomach | 30 days | 60 days | 90 days | |
| Heavy dose of group | 20 | 148.18±4.56 | 191.55±6.11 | 231.25±4.53 | 467.10±9.17 |
| Middle dosage group | 20 | 149.66±4.27 | 195.20±7.11 | 236.00±7.12 | 475.45±10.50 |
| Small dose group | 20 | 148.63±4.75 | 190.30±7.33 | 237.25±5.71 | 476.00±9.44 |
| Matched group | 20 | 148.18±4.32 | 194.20±8.03 | 239.70±5.59 | 469.10±9.41 |
The influence of table 4 pair routine blood test
| Project | Before the medication | After the medication | P |
| Hb(g/l) | 126.4±10.82 | 118.9±10.78 | ＞0.05 |
| BBC(×10 12/L) | 4.92±0.32 | 4.94±0.37 | ＞0.05 |
| WBC(×10 9/L) | 14.28±3.12 | 13.81±3.18 | ＞0.05 |
| PC(×10 9/L) | 196.78±79.19 | 98.75±80.23 | ＞0.05 |
The influence of table 5 pair liver function (ALT, TBLL, TP, ALB) renal function (BUN, CP)
| Project | Before the medication | After the medication | P |
| ALT(U/L) | 41.65±5.62 | 42.43±5.87 | ＞0.05 |
| TBLL(umol/L) | 13.65±1.62 | 13.46±1.64 | ＞0.05 |
| TP(B/L) | 61.43±3.69 | 602.98±3.84 | ＞0.05 |
| ALB(B/L) | 31.38±2.83 | 0.94±0.83 | ＞0.05 |
| BUN(mmol/L) | 6.86±0.84 | 6.94±0.83 | ＞0.05 |
| CP(mmol/L) | 98.32±8.24 | 97.34±9.24 | ＞0.05 |
The influence (± 3) of table 6 pair blood glucose (GLL) and blood fat (TC, TG)
| Project | Before the medication | After the medication | P |
| GLL(mmol/l) | 3.89±0.46 | 3.98±0.76 | ＞0.05 |
| TC(mmol/l) | 0.64±0.14 | 0.62±0.13 | ＞0.05 |
| TG(mmol/l) | 0.45±0.14 | 0.42±0.12 | ＞0.05 |
Three, to the influence of main organs tissue morphology: (seeing Table 7)
System becomes celestial: administration is put to death after 90 days and is become celestial:
The internal organs of 4 groups of rats (12 kinds of organs and tissues such as gland, stomach, small intestinal, large intestine, testis, ovary on the heart, liver, spleen, lung, kidney, adrenal gland, the breast) profile, size are normally, tangent plane shows no obvious abnormalities, also there is not significant difference between each group of organ coefficients such as its center, liver,spleen,kidney, only find that 4 rats of heavy dose of group have physogastry, all because of due to the heavy dose, after treating gastrointestinal emptying, above-mentioned symptom all disappears.
The influence of the internal organs weight/power ratio of the every 100g body weight of table 7 pair rat (± s.n=20)
| Internal organs | Heavy dose of group | Middle dosage group | Small dose group | Matched group |
| Heart (g) | 0.36±0.07 | 0.33±0.06 | 0.34±0.08 | 0.32±0.09 |
| Liver (g) | 4.23±0.58 | 4.14±0.57 | 4.16±0.62 | 4.11±0.68 |
| Spleen (g) | 0.25±0.09 | 0.24±0.06 | 0.23±0.08 | 0.22±0.07 |
| Lungs (g) | 0.75±0.17 | 0.72±0.19 | 0.73±0.16 | 0.71±0.18 |
| Kidney (g) | 0.68±0.08 | 0.66±0.09 | 0.63±0.10 | 0.64±0.07 |
| Adrenal gland (g) | 20.2±5.27 | 18.6±6.03 | 19.2±5.67 | 1.78±6.36 |
| Testis (g) | 1.04±0.17 | 1.01±0.14 | 1.02±0.13 | 0.99±0.15 |
| Ovary (g) | 40.6±10.4 | 39.8±10.7 | 38.4±11.8 | 37.6±12.4 |
Four, pathological section microscopy:
The heart: the endocardium of 4 groups of rats, adventitia, cardiac muscle fiber no abnormality seen, the cardiac muscle fiber band is clear.
Liver: the lobules of liver structure is normal, and hepatocyte is radial arrangement, does not see that hepatocyte distortion, downright bad, liver rope do not have that atrophy, central vein are not expanded, inflammatory cell infiltration is not seen in the portal area.
Spleen: 4 groups of rat splenic red pulps, white pulp boundary be clear, do not see inflammatory cell infiltration.
Lung: matched group has in the lung tissue of 3 rats, the broadening of exhaustion of lung-QI wall, and congested companion's lymphocyte and monocyte infiltration, heavy dose of group has 3 rats, small dose group to have 2 rats that similar pathological change is arranged.
Kidney: the boundary of skin medullary substance is clear, and 4 groups of kidney of rats bead sizes are normal, and blood capillary does not have congested expansion, does not see hyperplasia in the ball, and a matter is not also seen obvious hyperemia.
The adrenal gland: no abnormality seen changes.
1, maximum tolerance determination:
20 mouse stomach total amounts are 996mg, 124.5 times of quite clinical adult's dosage, and none example is dead, all survivals, reflection has no side effect.
2, long term toxicity is measured:
Each dosage ordinary circumstance is good, weight increase, routine blood test chemical examination, hepatic and renal function and blood lipid examination, all similar to matched group, no significant difference, 12 kinds of organs and tissues there is no special pathological change, chemical examination confirms to continue medication 90 days, 20 times of quite clinical consumptions, also avirulence performance.
Above-mentioned experiment shows, acute, toxicity and long term toxicity is all very little, oral, the abdominal cavity application safety can supply clinical practice.
Test is proof further: blood sugar lowering and glucose in urine degraded and absorbed under the gastric juice effect presents gel state significantly; volume gain; the food and extend emptying time; reduce postprandial hyperglycemia, alleviate, protect and recover its normal function the stimulation of insulin secretion and the burden of B cell; be not absorbed part and in intestinal, delay or reduce the absorption of sugared thing in the food because of very strong swelling is arranged; not only reduce and delay glycemic peaks, and promote that blood glucose excretes, thereby reach nature blood sugar lowering purpose.The excited hunger center of energy vagus nerve stimulation, cause the parasympathetic nervous excitement and make the small artery expansion, the mediation microcirculation, stagnant intercellular carbon dioxide and moisture are excreted, present faint alkali state, and stimulate B cell to impel its excreting insulin, increase of picked-up and the utilization of its hetero-organization of human body sugar, make the amount of insulin secretion trend normal, keep normal blood glucose metabolism.Can stop cholesterol and neutral fat to absorb and rising, promote the generation of hepatitis virus antibody, increase the vigor of aldehyde dehydrogenase, avoid the formation of fatty liver and repaired the hepatocyte that damages, strengthen liver function, many cureless hepatopaths are found in practice, and its symptom has improvement greatly.
Use proof through clinical 321 examples, total effective rate is 98.9%, and the diabetics initial stage is totally 82 examples, after obeying the medicine 5-6 month of the present invention, stop to obey the blood sugar lowering Western medicine, tracing observation did not have bounce-back in 2 years, the type ii diabetes patient cuts out all medicines, and tracing observation 2 years 06 months does not have bounce-back.
Mid-term diabetics 169 examples, take the medicine 3-4 month of the present invention, wherein 97.5% patient reduces clothes Western medicine amount 60%-70%, took medicine 10-12 of the present invention month, patient's minimizing of 96.8% is taken the Western medicine amount and is reached 85%, individual patient reaches 90%, and the type ii diabetes patient can cut out Western medicine, and tracing observation did not have bounce-back in 1 year 08 months.
Medical history is more than 15 years and with patient's 70 examples of complication, took medicine 3-4 of the present invention month, reduce clothes Western medicine amount and reach 50%, took 10-12 month, reduce clothes Western medicine amount 70%, take and to reduce clothes Western medicine amount 80% in 15 months, only need obey 20% of former Western medicine total amount every night, but and the next day clothes once, blood glucose, glucose in urine are normal substantially, self feels good, and tracing observation did not rebound in 2 years.
The specific embodiment
The embodiment of the invention:
Medicine of the present invention can adopt the following weight proportion raw material to make:
1, Carapax Trionycis 35g, Carapax et Plastrum Testudinis 35g, Stigma Croci 15g, Cornu Cervi Pantotrichum 15g.
2, Carapax Trionycis 40g, Carapax et Plastrum Testudinis 40g, Stigma Croci 10g, Cornu Cervi Pantotrichum 10g.
3, Carapax Trionycis 45g, Carapax et Plastrum Testudinis 45g, Stigma Croci 5g, Cornu Cervi Pantotrichum 5g.
4, Carapax Trionycis 38g, Carapax et Plastrum Testudinis 38g, Stigma Croci 14g, Cornu Cervi Pantotrichum 14g.
5, Carapax Trionycis 42g, Carapax et Plastrum Testudinis 42g, Stigma Croci 8g, Cornu Cervi Pantotrichum 8g.
Raw material Carapax Trionycis in the said medicine, Carapax et Plastrum Testudinis are through soda acid and decompose.
Above medicine adopts following method to make: put into container inner acidic liquid after Carapax Trionycis, Carapax et Plastrum Testudinis are cleaned and soaked 10-13 hour, preferred 12 hours, the weight of vinegar was the 6%-8% of clear water weight in the liquid, preferred 8%, property among taking-up is dashed with clear water after soaking is dried standby;
Above-mentioned standby Carapax Trionycis, Carapax et Plastrum Testudinis are put into akaline liquid again soaked 10-13 hour, preferred 12 hours, the weight of alkali was the 10%-12% of clear water weight in the akaline liquid, and is preferred 12%, soak the back take out clear water dash among property dry standby;
To put into acidic liquid for the second time through Carapax Trionycis, Carapax et Plastrum Testudinis that akaline liquid soaks and soak 10-13 hour, preferred 12 hours, the weight of the tablet vinegar in the liquid was the 4%-6% of clear water weight, and is preferred 5%, soak the back take out clear water dash among property, dry standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after the second time, acidic liquid soaked are put into akaline liquid again soaked 10-13 hour, preferred 12 hours, the weight of the alkali in the liquid was the 8%-10% of clear water weight, and is preferred 10%, soak the back take out clear water dash among property, dry standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after will handling through above-mentioned operation be put into inherent 78 ℃-82 ℃ of constant temperature oven, and insulation is 46-50 hour in preferred 80 ℃ of scopes, preferred 48 hours, take out that to be crushed to powdery after the oven dry standby;
Cornu Cervi Pantotrichum inserted in the steam steamed 2-3 hour, preferred 2 hours, add at the clear water that is used for producing steam and to account for clear water weight 8%-10% rice wine, preferred 9%, drying the back oven drying at low temperature, to be crushed to powdery standby;
Stigma Croci is cleaned the back oven drying at low temperature, and to be crushed to powdery standby;
To make medicine of the present invention behind above-mentioned turtle ' s carapace powder, Tortoise Shell, Pulveratum Cornu Cervi Pantotrichum and the safranine pollen mix homogeneously.The vinegar that uses in the acidic liquid described in the inventive method is tablet vinegar.
The described medicine of inventing is capsule, powder or tablet, and every capsules, tablet contain 5 gram medicines respectively.
Every day obeyed twice by medicine of the present invention, each 10 grams, sooner or later respectively once.
Claims (6)
1. medicine for the treatment of diabetes, it is characterized in that: it is made by the following weight proportion raw material: the Carapax Trionycis 35-45 part after decomposing through soda acid, the Carapax et Plastrum Testudinis 35-45 part after decomposing through soda acid, Cornu Cervi Pantotrichum 5-15 part, Stigma Croci 5-15 part.
2. a kind of medicine for the treatment of diabetes according to claim 1, it is characterized in that: it is made by the following weight proportion raw material, and 40 parts of the Carapax Trionycis after decomposing through soda acid are through 40 parts of the Carapax et Plastrum Testudiniss after the soda acid decomposition, 10 parts in Cornu Cervi Pantotrichum, 10 parts of Stigma Crocis.
3. claim 1 or 2 each described a kind of preparation methoies for the treatment of the medicine of diabetes, it is characterized in that: put into container after Carapax Trionycis, Carapax et Plastrum Testudinis are cleaned and soaked 10-13 hour with acidic liquid, the weight of vinegar is the 6%-8% of clear water weight in the liquid, property among taking-up is dashed with clear water after soaking is dried standby;
Above-mentioned standby Carapax Trionycis, Carapax et Plastrum Testudinis are put into akaline liquid again soaked 10-13 hour, the weight of alkali is the 10%-12% of clear water weight in the akaline liquid, and property was dried standby among the taking-up clear water dashed after soaking;
To put into acidic liquid for the second time through Carapax Trionycis, Carapax et Plastrum Testudinis that akaline liquid soaks and soak 10-13 hour, the weight of vinegar is the 4%-6% of clear water weight in the liquid, and property among the taking-up clear water dashes after soaking is dried standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after the second time, acidic liquid soaked are put into akaline liquid again soaked 10-13 hour, the weight of the alkali in the liquid is the 8%-10% of clear water weight, and property among the taking-up clear water dashes after soaking is dried standby;
Carapax Trionycis, Carapax et Plastrum Testudinis after will handling through above-mentioned operation be put into inherent 78 ℃ of-82 ℃ of scopes insulation of constant temperature oven 46-50 hour, take out that to be crushed to powdery after drying standby;
Cornu Cervi Pantotrichum inserted in the steam steamed 2-3 hour, add the rice wine that accounts for clear water weight 8%-10% at the clear water that is used for producing steam, the Cornu Cervi Pantotrichum after steaming is dried the back oven drying at low temperature, and to be crushed to powdery standby;
Stigma Croci is cleaned the back oven drying at low temperature, and to be crushed to powdery standby;
To make medicine of the present invention behind above-mentioned turtle ' s carapace powder, Tortoise Shell, Pulveratum Cornu Cervi Pantotrichum and the safranine pollen mix homogeneously.
4. a kind of preparation method for the treatment of the medicine of diabetes according to claim 3, it is characterized in that: made medicine is a capsule.
5. a kind of preparation method for the treatment of the medicine of diabetes according to claim 3, it is characterized in that: made medicine is a powder.
6. a kind of preparation method for the treatment of the medicine of diabetes according to claim 3, it is characterized in that: made medicine is a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710114011A CN100586445C (en) | 2007-10-31 | 2007-10-31 | Medicine for treating diabetes and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710114011A CN100586445C (en) | 2007-10-31 | 2007-10-31 | Medicine for treating diabetes and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101167899A true CN101167899A (en) | 2008-04-30 |
| CN100586445C CN100586445C (en) | 2010-02-03 |
Family
ID=39388747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710114011A Expired - Fee Related CN100586445C (en) | 2007-10-31 | 2007-10-31 | Medicine for treating diabetes and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100586445C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105410928A (en) * | 2015-10-29 | 2016-03-23 | 重庆乐然农业科技有限公司 | Preparation method of composition capable of expelling toxins and nourishing blood |
| CN105596392A (en) * | 2016-01-15 | 2016-05-25 | 白云兵 | Medicine for tonifying kidney |
| CN108743783A (en) * | 2018-08-29 | 2018-11-06 | 齐爱萍 | A kind of Chinese medicine for treating diabetes |
| CN112076241A (en) * | 2020-10-30 | 2020-12-15 | 禾门生物(广东)有限公司 | Traditional Chinese medicine preparation for preventing yin deficiency and internal heat |
-
2007
- 2007-10-31 CN CN200710114011A patent/CN100586445C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105410928A (en) * | 2015-10-29 | 2016-03-23 | 重庆乐然农业科技有限公司 | Preparation method of composition capable of expelling toxins and nourishing blood |
| CN105596392A (en) * | 2016-01-15 | 2016-05-25 | 白云兵 | Medicine for tonifying kidney |
| CN108743783A (en) * | 2018-08-29 | 2018-11-06 | 齐爱萍 | A kind of Chinese medicine for treating diabetes |
| CN112076241A (en) * | 2020-10-30 | 2020-12-15 | 禾门生物(广东)有限公司 | Traditional Chinese medicine preparation for preventing yin deficiency and internal heat |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100586445C (en) | 2010-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN100586445C (en) | Medicine for treating diabetes and its preparation method | |
| CN101433568A (en) | Extraction of burdock root aqueous extract and use | |
| CN101450101A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| WO2005074952A1 (en) | Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof | |
| CN101433667A (en) | Pharmaceutical composition with function for reducing blood sugar and preparation method thereof | |
| CN110432500A (en) | A kind of prebiotic compositions and preparation method and purposes containing inulin | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN101301284B (en) | Uses of emodic acid or salt thereof for treating chronic nephritis or chronic renal failure | |
| CN1114418C (en) | Medicine for rheumatism and aploplexy and its preparation | |
| CN102772596A (en) | Weight-losing and vein-dredging capsules and preparation technology thereof | |
| CN101791351B (en) | Glipizide-containing traditional Chinese and western medicine composition | |
| CN107281408A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| US11224607B2 (en) | Anticancer composition of traditional Chinese medicine and preparation method thereof | |
| CN107811907A (en) | A kind of body lotion for promoting subcutaneous fat to decompose | |
| CN101791350B (en) | Glibenclamide-containing traditional Chinese and western medicine composition | |
| CN100363000C (en) | Chinese and western medicines composition contg. Avandia and its prepn. method | |
| CN1299755C (en) | Cinnamon compound medicine, and its preparing method and use | |
| CN107998117B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN1234404C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN101450096A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN1557402A (en) | Chinese herbal medicine preparation and its preparing process and application | |
| CN100362998C (en) | Medicine composition for treating diabetes | |
| CN102846778B (en) | Chinese medicinal formulation for treating burn and scald and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100203 Termination date: 20191031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |